Holen Sie sich die Stockscreener-App
17.11
0.29%
-0.05
Handel nachbörslich:
17.11
Schlusskurs vom Vortag:
$17.16
Offen:
$17.18
24-Stunden-Volumen:
358.04K
Relative Volume:
0.79
Marktkapitalisierung:
$6.10B
Einnahmen:
$5.21B
Nettoeinkommen (Verlust:
$-211.00M
KGV:
-27.69
EPS:
-0.6179
Netto-Cashflow:
$861.30K
1W Leistung:
+2.89%
1M Leistung:
+10.67%
6M Leistung:
-0.06%
1J Leistung:
+23.27%
1-Tages-Spanne:
$16.99
$17.21
1-Wochen-Bereich:
$16.32
$17.25
52-Wochen-Spanne:
$13.09
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.11 | 5.90B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
432.83 | 140.84B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
155.54 | 41.70B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.75 | 33.35B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
68.33 | 32.72B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
218.40 | 28.27B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Bausch + Lomb survey finds dry eye symptoms linked to emotional health impacts - Optometry Times
Dry eye treatment tied to lower anxiety, better confidence in Bausch + Lomb survey - Stock Titan
Bausch + Lomb Corp updates investors on strategic focus, shares trade on NYSE - AD HOC NEWS
INFUSE silicone hydrogel daily contact lenses from Bausch + Lomb Corp.a moisture-first take on al - AD HOC NEWS
BLCO Forecast — Price Target — Prediction for 2027 - TradingView
S2L Forecast — Price Target — Prediction for 2027 - TradingView
Bausch + Lomb Corporation Actuals & Estimates (NYSE:BLCO) - TradingView
Bausch + Lomb Corporation Actuals & Estimates (TSX:BLCO) - TradingView
Bausch + Lomb Tumbles as Technical and Governance Fears Mount - TipRanks
(BLCO) Risk Channels and Responsive Allocation - Stock Traders Daily
INFUSE Multifocal from Bausch + Lomb Corp.daily disposable lens for presbyopia - AD HOC NEWS
Cooper Cos. gains after report activist Jana takes stake - MSN
Bausch + Lomb (BLCO) Consolidates Near Support Following Minimal Daily ChangeFloat Adjusted Cap - dars.gov.et
Bausch + Lomb Corp (BLCO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bausch + Lomb Corp (BLCO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bausch + Lomb Corp (BLCO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bausch + Lomb Corp (BLCO) Institutional Confidence - TradingKey
Bausch + Lomb Corp (BLCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bausch + Lomb Corp (BLCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bausch + Lomb Corp (BLCO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bausch + Lomb Corp (BLCO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bausch + Lomb Corp (BLCO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bausch & Lomb (NYSE: BLCO) executive has 1,008 shares withheld for tax on RSU vesting - Stock Titan
Emmetrope Ophthalmics LLC announced that it has received funding from Bausch + Lomb Corporation - marketscreener.com
Bausch + Lomb Corporation (BLCO): Investor Outlook With An 18.53% Potential Upside - DirectorsTalk Interviews
(BLCO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Bausch + Lomb to lay off employees in Missouri - Yahoo Finance
Transcript : Bausch + Lomb Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01 - marketscreener.com
Bausch + Lomb Dry Eye Launch Highlights Valuation Gap And Growth Questions - Yahoo Finance
Why Bausch + Lomb Corp stock is sliding today - Wealth Awesome
Bausch + Lomb Corporation (BLCO): Investor Outlook and Potential 15.62% Upside in the Healthcare Sector - DirectorsTalk Interviews
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Blink Triple Care Preservative Free U.S. Launch - Sahm
Will Blink Triple Care’s Preservative Free Launch Reshape Bausch + Lomb’s (BLCO) Consumer Eye Care Narrative? - webull.com
Bausch + Lomb’s New Dry Eye Launch And What It Means For BLCO - Sahm
RBC Capital reiterates Bausch & Lomb stock rating at Outperform By Investing.com - Investing.com Australia
RBC Capital reiterates Bausch & Lomb stock rating at Outperform - Investing.com
Bausch + Lomb Corp stock (CA07174N1090): valuation metrics in focus after recent trading in Toronto - AD HOC NEWS
Bausch + Lomb Insiders Added US$2.46m Of Stock To Their Holdings - Moomoo
Liquidity Mapping Around (BLCO) Price Events - Stock Traders Daily
Bausch + Lomb (BLCO) R&D Day 2026 Summary - Quartr
BLCO.CA Stock Price, Quote & Chart | BAUSCH + LOMB CORP (TSX:BLCO) - ChartMill
Bausch + Lomb launches preservative-free dry eye drops in U.S. By Investing.com - Investing.com South Africa
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States - BioSpace
Preservative-free eye drops offer up to 10 hours dry-eye relief - Stock Titan
Bausch + Lomb Corporation (BLCO) Investor Outlook: Analyzing Growth Potential with a 14% Upside - DirectorsTalk Interviews
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch & Lomb (BLCO) director awarded 15,842 RSUs under 2022 Omnibus Incentive Plan - Stock Titan
Bausch & Lomb (NYSE: BLCO) grants 15,842 RSUs to director - Stock Titan
Bausch & Lomb (NYSE: BLCO) director awarded 15,842-share RSU grant - Stock Titan
Bausch & Lomb (BLCO) director John Paulson receives 15,842-share RSU grant - Stock Titan
Bausch & Lomb (BLCO) director Karen Ling awarded 15,842 RSUs as annual equity grant - Stock Titan
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bausch Lomb Corp-Aktie (BLCO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Eldessouky Sam | EVP and CFO |
Mar 06 '26 |
Buy |
17.13 |
4,000 |
68,520 |
403,130 |
| SAUNDERS BRENT L | CEO and Chairman of the Board |
Mar 06 '26 |
Buy |
17.14 |
14,700 |
251,958 |
966,575 |
| Ross Thomas W. Sr. | Director |
Mar 03 '26 |
Buy |
17.68 |
4,500 |
79,556 |
64,891 |
| Alfonso Eduardo | Director |
Mar 02 '26 |
Buy |
17.90 |
4,300 |
76,970 |
9,555 |
| VON ESCHENBACH ANDREW C. | Director |
Feb 27 '26 |
Buy |
18.30 |
4,364 |
79,883 |
66,450 |
| COLLIS STEVEN H | Director |
Feb 23 '26 |
Buy |
17.81 |
15,000 |
267,150 |
20,255 |
| ROBERTSON RUSSEL C | Director |
Feb 20 '26 |
Buy |
17.90 |
4,400 |
78,760 |
72,407 |
| Ling Karen | Director |
Feb 19 '26 |
Buy |
17.74 |
4,000 |
70,968 |
41,676 |
0.31%
2.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):